🔗 Visit the ClinicalTrials.gov page for NCT02128061
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. | Mol Cancer | 2015 | 0.94 |
| 2 | Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. | Rare Tumors | 2015 | 0.75 |